Aristotle University Of Thessaloniki (AUTH)
Φαρμακογενετική μελέτη της αναστολής της ενδοθηλιακής λιπάσης, ως μέσου αύξησης της HDL-χοληστερόλης: ο ρόλος του πολυμορφισμού LIPG 584 C/T
Abstract
dc:descriptionIncreasing low levels of HDL-C levels is an important target for effective reduction of residual cardiovascular risk. Endothelial lipase (EL) is an enzyme that degrades HDL and is correlated inversely with HDL-C levels, constituting a potential target for pharmaceutical intervention that has not been adequately studied to date. The purpose of this study was to assess the association of the change in serum EL concentration with the change in HDL-C levels after hypolipidemic treatment, and more specifically with rosuvastatin, fenofibrate and nicotinic acid/laropiprant, as well as the investigation of the effect of common polymorphism 584 C/T of EL (LIPG 584 C/T) at the above changes. One hundred and seven dyslipidemic patients (99 women; median age: 59 years old) without history of secondary dyslipidemia, and not receiving any hypolipidemic treatment were included in our study. Eighty six normolipidemic individuals (40 women) constituted the control group. The dyslipidemic patients were classified into 3 groups depending on the pharmaceutical 3-month intervention (intervention Groups) according to their prominent lipid abnormality and cardiovascular risk, as follow: Group A (rosuvastatin, 10 mg/day):70 patients, Group B (fenofibrate, 200 mg/day):70 patients, Group C (extended-releasenicotinic acid/laropiprant, 1000 mg/20 mg once a day for 4 weeks, thereafter 2000 mg/40 mg once daily): 47 patients. The baseline levels of lipidemic parameters such as EL, HDL-C, T-C, LDL-C, TRG, apoA-I, apoB as well as inflammatory markers hs-CRP, TNF-a, IL-1, IL-6, and biochemical parameters (CPK, SGPT, HbA1C%, eGFR) were measured in all participants in the study. The changes in the levels of lipidemic, inflammatory, and biochemical parameters were assessed in each intervention Group at the end of the study, and were comparatively evaluated. Additionally, the polymorphism LIPG 584 C/T was genotyped in all participants. The statistical analysis was performed using SPSS v. 22.0 statistical software. Before drug treatment, the results of our study revealed that EL levels were significantly higher in dyslipididemics compared to normolipidemics, as well as in obese individuals regardless of lipid disorder. Also, EL was significantly negatively correlated with HDL-C and apoA-I, and emerged as an independent significant predictor of HDL-C levels that could explained 44% of its levels variation in the dyslipidemic group. At the same time, the inflammatory markers hs-CRP and IL-6 were significant correlated with EL and HDL-C (positively and negatively, respectively. In contrast, in the normolipidemic group a significant mildly correlation of EL both with HDL-C and apoA-I was found, as well as a marginal significant correlation with hs-CRP. The LIPG 584 C/T polymorphism was detected in 93% of the total study population. In the dyslipidemic group the recessive allele T was associated with higher baseline levels of HDL-C, apoA-I and lower baselines levels of EL, T-C, LDL-C, apoB, hs-CRP, TNF-α, IL-1, IL-6 compared with the dominant allele C. In contrast, in the control group no significant associations were detected in the baseline levels of lipidemic and inflammatory parameters in relation with polymorphism 584 C/T genotypes apart from the case of TNF-α where a marginally significant association with the carriers of the T allele was found. Following drug treatment, there was significant increase of HDL-C and apoA-I levels and a respective decrease of EL T-C, TRG, hs-CRP, TNF-α, IL-1, IL-6, in all intervention Groups (Α, B, C), as well as significant decrease of LDL-C and apoB in Groups A and C. The EL change was significantly correlated with HDL-C change in all intervention Groups independently of age, sex, BMI, constituting an important predictor of HDL-C change (A: 23.4%, B: 44%, C: 30%). Similarly, the EL change was significantly correlated with apoA-I change in Groups A and B independently of age, sex, BMI. In Group B, the recessive allele T was associated with significantly greater increases in HDL-C and apoA-I levels (as homozygous TT) as well as greater reductions in EL and IL-6 levels (as T carriage; CT+TT) than the dominant allele C. In the contrary, the dominant allele C was associated with significantly greater TRG reductions compared with the recessive allele (TT and CT+TT genotypes) in Groups A and B. In 16% of the genotyped dyslipidemic patients a negative change from baseline levels of HDL-C was detected. The majority of these cases were dominant homozygous genotypes CC. In Group B as well as in the total dyslipidemic population (A+B+C), that overrepresentation of the CC genotypes was significant. In conclusion, EL has a significant effect on the modulation of low levels of HDL-C and is positively correlated with the inflammatory process in dyslipidaemia. The decrease in EL levels following all three types of hypolipidemic treatment was associated with the increase in HDL-C levels and constitutes a significant predictor of changes in HDL-C levels. The polymorphism LIPG 584 C/T is significant associated with the baseline levels of HDL-C in recently diagnosed dyslipidemics. The recessive allele T of polymorphism LIPG 584 C/T has a positive impact on achieving a greater increase in HDL-C, especially after fenofibrate use. The dominant homozygous genotype of polymorphism LIPG 584 C/T is generally related to a paradoxical reduction in HDL-C levels following the specific hypolipidemic therapy, especially and significant after fenofibrate use. The clinical utility of our results relates to the possible use of the detection of this polymorphism in predicting the drug response to HDL-C (or/and TRG/non-HDL) levels as well as inflammatory markers, when selecting the particular drugs studied in the study, in an effort to maximize the cardiovascular benefit by hypolipidemic treatment with these drugs.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Agapakis, Dimitris
- Αγαπάκης, Δημήτριος
Subjects
dc:subject × 8Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40946